Professional
Added to YB: 2026-10-14
Pitch date: 2026-10-06
ILA.AX [bullish]
Island Pharmaceuticals Limited
-10.53%
current return
Author Info
Research as a Service is Australia’s leading independent investment research house sharing institutional-quality, issuer-sponsored research. Sign up for the newsletter.
Company Info
Island Pharmaceuticals Limited, a drug repurposing company, focuses on the development of antiviral therapeutics for infectious diseases in Australia and the United States.
Market Cap
AUD 108.1M
Pitch Price
AUD 0.38
Price Target
1.60 (+371%)
Dividend
N/A
EV/EBITDA
-9.31
P/E
-10.02
EV/Sales
336.82
Sector
Pharmaceuticals
Category
special_situation
Island Pharmaceuticals (ASX:ILA) - Galidesivir manufacturing underway for Ebola deployment
ILA.AX (hold): Island Pharmaceuticals has begun GMP manufacturing of Galidesivir API, moving its antiviral programmes toward execution: a first 5kg batch expected by end-October is earmarked for approved emergency use in Uganda and potential human Ebola data, while a second batch planned by end-November supports Ebola and a pivotal Marburg study. The unchanged rNPV is $1.60/share at 65% probability of success, reflecting binary milestones over 18 months.
Read full article (2 min)